This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 2
  • /
  • FDA supplemental approval for Gocovri as an adjunc...

FDA supplemental approval for Gocovri as an adjunctive treatment to levodopa/carbidopa in Parkinson’s disease patients experiencing OFF episodes. Adamas Pharma

Read time: 1 mins
Published:4th Feb 2021
Adamas Pharmaceuticals, Inc., a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, announced it has received marketing authorization from the FDA for a supplemental New Drug Application for Gocovri (amantadine) extended release capsules, gaining a second indication for the product. Gocovri is now approved as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing OFF episodes, in addition to its indication for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. Data from two pivotal, placebo-controlled Phase III clinical studies showed that treatment with Gocovri significantly reduced both OFF time and dyskinesia. This resulted in a clinically meaningful increase in good ON time in patients taking a levodopa-based medication for Parkinson’s disease. Additionally, Gocovri demonstrated sustained efficacy for at least two years in the Phase III, open-label EASE LID-2 study.
Condition: Parkinsons-LID
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.